- Home
- OPT vs ORIC Comparison
OPT vs ORIC Comparison
Compare OPT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- ORIC
- Stock Information
- Founded
- OPT 1984
- ORIC 2014
- Country
- OPT Australia
- ORIC United States
- Employees
- OPT N/A
- ORIC N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- OPT Health Care
- ORIC Health Care
- Exchange
- OPT Nasdaq
- ORIC Nasdaq
- Market Cap
- OPT 855.6M
- ORIC 735.3M
- IPO Year
- OPT 2020
- ORIC 2020
- Fundamental
- Price
- OPT $5.09
- ORIC $7.68
- Analyst Decision
- OPT Strong Buy
- ORIC Strong Buy
- Analyst Count
- OPT 1
- ORIC 10
- Target Price
- OPT $12.00
- ORIC $19.13
- AVG Volume (30 Days)
- OPT 40.1K
- ORIC 1.6M
- Earning Date
- OPT 03-03-2025
- ORIC 02-18-2025
- Dividend Yield
- OPT N/A
- ORIC N/A
- EPS Growth
- OPT N/A
- ORIC N/A
- EPS
- OPT N/A
- ORIC N/A
- Revenue
- OPT $261,859.00
- ORIC N/A
- Revenue This Year
- OPT N/A
- ORIC N/A
- Revenue Next Year
- OPT $46,864.26
- ORIC N/A
- P/E Ratio
- OPT N/A
- ORIC N/A
- Revenue Growth
- OPT N/A
- ORIC N/A
- 52 Week Low
- OPT $1.79
- ORIC $6.33
- 52 Week High
- OPT $6.30
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- OPT 53.99
- ORIC 36.65
- Support Level
- OPT $4.77
- ORIC $7.34
- Resistance Level
- OPT $5.46
- ORIC $14.67
- Average True Range (ATR)
- OPT 0.32
- ORIC 1.56
- MACD
- OPT -0.11
- ORIC -0.45
- Stochastic Oscillator
- OPT 20.60
- ORIC 4.64
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.